Correction: Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring

Correction: Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring

Saved in:

Bibliographic Details
Main Authors:	Chunyan Liu, Fang Fang, Ying Kong, Ehab A. ElGabry
Format:	Article
Language:	English
Published:	BMC 2025-02-01
Series:	Diagnostic Pathology
Online Access:	https://doi.org/10.1186/s13000-025-01605-6
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring
by: Chunyan Liu, et al.
Published: (2023-04-01)

Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study
by: Yuequan Shi, et al.
Published: (2025-07-01)

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01)

Prevalence and prognostic value of the programmed cell death-ligand 1 (PD-L1) expression among tumor samples from cervical cancer patients
by: Michelle Marques Lessa, et al.
Published: (2022-10-01)

Prediction of PD-L1 tumor positive score in lung squamous cell carcinoma with H&E staining images and deep learning
by: Qiushi Wang, et al.
Published: (2024-12-01)

Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade
by: Peng Liu, et al.
Published: (2025-06-01)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
by: Valerie Chew, et al.
Published: (2020-10-01)

Prognostic score models for acquired resistance to frontline anti-programmed cell death protein 1/programmed death-ligand 1 therapy in metastatic non-small-cell lung cancer
by: J.C. Murray, et al.
Published: (2025-06-01)

Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade
Published: (2025-06-01)

Relationship Between Short‐Term Outcomes and PD‐L1 Expression Based on Combined Positive Score and Tumor Proportion Score in Recurrent or Metastatic Head and Neck Cancers Treated With Anti‐PD‐1 Antibody Monotherapy
by: Akihiro Ohara, et al.
Published: (2025-01-01)

Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages
by: Di Lu, et al.
Published: (2019-01-01)

Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo
by: Hanan R. Nada, et al.
Published: (2025-01-01)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
by: Megan Schollenberger, et al.
Published: (2017-08-01)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
by: Samit Chatterjee PhD, et al.
Published: (2017-07-01)

Programmed death ligand 1 (PD-L1) expression in gastric cancer: literature review
by: T. N. Sotnikova, et al.
Published: (2023-07-01)

Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with peripheral T-cell lymphoma: a meta-analysis
by: Ying Wu, et al.
Published: (2025-12-01)

Loss of MNX1 Sensitizes Tumors to Cytotoxic T Cells by Degradation of PD‐L1 mRNA
by: Zhengzheng Li, et al.
Published: (2025-03-01)

Combination radiation and αPD-L1 enhance tumor control by stimulating CD8+ PD-1+ TCF-1+ T cells in the tumor-draining lymph node
by: Yang Shen, et al.
Published: (2025-04-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
by: A. Yu. Kalinchuk, et al.
Published: (2024-03-01)

Tumor-derived immunoglobulin-like transcript 3 inhibition reshapes the immunosuppressive tumor microenvironment and potentiates programmed cell death ligand 1 blockade immunotherapy in lung adenocarcinoma
by: Leirong Wang, et al.
Published: (2025-06-01)

The Prognostic Value of Serum Soluble Programmed Death 1 (sPD‐1) and Programmed Death Ligand 1 (sPD‐L1) in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis About Cohort Studies
by: Qiyao Yu, et al.
Published: (2024-11-01)

Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with colorectal cancer: a meta-analysis
by: Jichao Zhu, et al.
Published: (2025-07-01)

Prognostic value of human papilloma virus (HPV) status and programmed cell death ligand 1 (PD-L1) status in oral tongue cancer
by: Mateusz Szewczyk, et al.
Published: (2024-11-01)

Tyrosinase in melanoma inhibits anti-tumor activity of PD-1 deficient T cells
by: Rong Huang, et al.
Published: (2025-05-01)

ZEB1 transcription factor induces tumor cell PD-L1 expression in melanoma
by: Chloé Wirbel, et al.
Published: (2025-03-01)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
by: Bhumsuk Keam, et al.
Published: (2020-10-01)

PD-L1 expression on tumor cells and tumor-infiltrating immune cells in thymic epithelial tumors detected with SP142 and SP263 antibodies.
by: Kei Chubachi, et al.
Published: (2025-01-01)

PD-L1 expression on tumor cells and tumor-infiltrating immune cells in thymic epithelial tumors detected with SP142 and SP263 antibodies
by: Kei Chubachi, et al.
Published: (2025-01-01)

Influence of programmed death ligand 1 (PD-L1) knockout on gut microbiota in experimental autoimmune uveitis
by: Junxiang Gu, et al.
Published: (2025-05-01)

NIR-II photo-accelerated polymer nanoparticles boost tumor immunotherapy via PD-L1 silencing and immunogenic cell death
by: Tian Zhang, et al.
Published: (2025-04-01)

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
by: Taiki Kurino, et al.
Published: (2020-05-01)

PD-1IR2 promotes tumor evasion via deregulating CD8+ T cell function
by: Xiaodong Wang, et al.
Published: (2025-03-01)

Tumor derived cell‐free nucleic acid upregulates programmed death‐ligand 1 expression in neutrophil via intracellular Toll‐like receptor signaling
by: Suguru Saito, et al.
Published: (2025-01-01)

PD-L1 on Circulating Tumor Cells Indicates Poor Prognosis in Breast Cancer
by: Xue-fei Wang, et al.
Published: (2022-11-01)

PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells
by: Cecilia Pesini, et al.
Published: (2022-12-01)

The accumulation of myeloid‐derived suppressor cells participates in abdominal infection‐induced tumor progression through the PD‐L1/PD‐1 axis
by: Yiding Wang, et al.
Published: (2025-05-01)

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
by: Diana I. Albu, et al.
Published: (2024-12-01)

Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma
by: Xiao Wu, et al.
Published: (2020-01-01)

Nasopharyngeal Carcinoma Subtype Discovery via Immune Cell Scores from Tumor Microenvironment
by: Yanbo Sun, et al.
Published: (2023-01-01)

Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1.
by: Shoba Amarnath, et al.
Published: (2010-02-01)